苯达莫司汀联合利妥昔单抗方案对原发性淋巴结边缘区B细胞淋巴瘤有效。

The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.

作者信息

Laribi Kamel, Tempescul Adrien, Ghnaya Habib, Denizon Nathalie, Besançon Anne, Anghel Andreea, Farhi Jonathan, Truong Catherine, Lemaire Pierre, Poulain Stephanie, Bolle Delphine, Ianotto Jean Christophe, Baugier de Materre Alix

机构信息

Department of Hematology, Centre Hospitalier du Mans, Le Mans, France.

Department of Hematology, Institut de Cancéro-Hématologie, CHRU Brest, Brest, France.

出版信息

Hematol Oncol. 2017 Dec;35(4):536-541. doi: 10.1002/hon.2334. Epub 2016 Jul 22.

DOI:10.1002/hon.2334

PMID:27443419

Abstract

Primary nodal marginal zone lymphoma (NMZL) is a rare disease. There is no current consensus on how to treat it. The bendamustine plus rituximab (BR) regimen is effective for the treatment of follicular and other indolent lymphomas, but its efficacy in NMZL is not known. We analyzed the outcome of 14 patients diagnosed with NMZL (median age 67 years) who were treated with 375 mg/m of rituximab on day 1 and 90 mg/m of bendamustine on days 1 and 2. The overall and complete response rates were 93% and 71%, respectively. Major toxicity (grade 3/4 neutropenia) occurred in 5% of treatment courses. After a median follow-up of 22 months (range: 18-55), the overall survival and the free survival rates were 100% and 93%, respectively. None of the patients showing a complete or partial response developed secondary myelodysplastic syndrome/acute myeloid leukemia. Bendamustine plus rituximab was found to be an active and well-tolerated regimen leading to the rapid control of disease.

摘要

原发性结内边缘区淋巴瘤（NMZL）是一种罕见疾病。目前对于如何治疗该病尚无共识。苯达莫司汀联合利妥昔单抗（BR）方案对滤泡性淋巴瘤和其他惰性淋巴瘤的治疗有效，但其在NMZL中的疗效尚不清楚。我们分析了14例诊断为NMZL的患者（中位年龄67岁）的治疗结果，这些患者在第1天接受375 mg/m的利妥昔单抗治疗，在第1天和第2天接受90 mg/m的苯达莫司汀治疗。总缓解率和完全缓解率分别为93%和71%。5%的治疗疗程出现了主要毒性（3/4级中性粒细胞减少）。中位随访22个月（范围：18 - 55个月）后，总生存率和无进展生存率分别为100%和93%。所有达到完全或部分缓解的患者均未发生继发性骨髓增生异常综合征/急性髓系白血病。结果发现，苯达莫司汀联合利妥昔单抗是一种有效且耐受性良好的方案，能迅速控制疾病。